Sensei Biotherapeutics, Inc. has announced promising clinical results from the dose-escalation segment of its Phase 1/2 study on SNS-101.

Coherus BioSciences, Inc. presented results from the CHS-114 monotherapy dose escalation part of its Phase 1 trial at the ASCO Annual Meeting.

Cure Genetics Revealed Positive Safety and Effectiveness Data for CAR-NKT Treatment CGC729 in RCC at ASGCT 2024.

Abdera Therapeutics Inc. has revealed that the U.S. Food and Drug Administration has approved their Investigational New Drug application for ABD-147.

Aulos Bioscience revealed preliminary outcomes from its Phase 1/2 study of AU-007.

Celltrion gains European Commission approval for Omlyclo® (CT-P39), the first omalizumab biosimilar sanctioned in Europe.

The European Medicines Agency (EMA) has approved the filings by Henlius and Organon for their biosimilar candidate HLX14 to Prolia® and Xgeva® (denosumab).

Kymera Therapeutics Unveils Novel Preclinical Findings for KT-621, an Oral STAT6 Degrader, at ATS Conference.

Scholar Rock begins Phase 2 EMBRAZE trial for Apitegromab and reveals new preclinical results for SRK-439 in treating obesity.

Zai Lab Limited announced the dosing of the first participant in a global Phase 2 trial of its anti-IL-17 treatment, ZL-1102, for chronic plaque psoriasis.

Dyne Therapeutics Reveals Latest Clinical Results from ACHIEVE Study of DYNE-101 in DM1 and DELIVER Study of DYNE-251 in DMD Highlighting Significant Effects on Key Disease Indicators and Improvements in Several Functional Outcomes.

AT278 Ultra-Concentrated Rapid-Acting Insulin Shows Superiority in Phase I Trial for Overweight and Obese Type 2 Diabetics.